Ultragenyx's DTX401 Faces August 23 PDUFA Date With No Approved Competition in GSD-Ia

Ultragenyx Pharmaceutical (NASDAQ: RARE) has a hard regulatory date on the calendar: the FDA's August 23, 2026 PDUFA decision on DTX401 (pariglasgene brecaparvovec), an AAV8 gene therapy for Glycogen Storage Disease Type Ia — a rare metabolic disorder with zero approved pharmacologic treatments on the market.

The FDA accepted the Biologics License Application and granted Priority Review on February 23, 2026, per the company's investor relations news release. The agency has since informed Ultragenyx that an Advisory Committee meeting is not anticipated, removing one layer of pre-approval uncertainty.

The BLA rests on data from 52 treated patients with up to six years of follow-up. The Phase 3 GlucoGene study hit its primary endpoint: at Week 48, the DTX401 group (n=20) achieved a mean 41.3% reduction in daily cornstarch intake versus 10.3% in the placebo group (n=24), with a p-value below 0.0001. Cornstarch dosing is the standard dietary intervention used to prevent hypoglycemic episodes in GSD-Ia patients — a proxy for how well the liver is managing glucose. By Week 96, the DTX401 group showed a mean 70% reduction in nighttime cornstarch, and a crossover group showed a mean 75% reduction; two-thirds of participants across both groups eliminated at least one nighttime cornstarch dose entirely.

DTX401 is administered as a single intravenous infusion, delivering stable expression of glucose-6-phosphatase (G6Pase) via an AAV8 vector under the control of the native promoter. The therapy is designed to allow treated liver cells to respond to normal hormonal signals — including insulin and cortisol — to manage glucose. The BLA package was completed with the submission of the chemistry, manufacturing, and controls module.

Eric Crombez, M.D., chief medical officer at Ultragenyx, framed the unmet need directly: "Current dietary approaches to managing GSDIa place an extraordinary burden on individuals and families while still leaving patients with significant medical needs, including the risk of potentially life-threatening episodes of acute hypoglycemia and accumulation of long-term complications over their lifetime."

The FDA has granted DTX401 four designations: Rare Pediatric Disease, orphan drug, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT). The European Medicines Agency has granted orphan drug and PRIME designations. GSD-Ia is estimated to affect approximately 6,000 people in commercially accessible geographies.

Ultragenyx is not running a single regulatory bet here. The company's AAV gene therapy UX111 (rebisufligene etisparvovec), for Sanfilippo syndrome type A (MPS IIIA), had its resubmitted BLA accepted by the FDA in April 2026 for accelerated approval, with a PDUFA date of September 19, 2026 — meaning the company faces two separate gene therapy FDA decisions, on August 23 and September 19, 2026.

The financial backdrop is relevant context. In its February 12, 2026 earnings report, Ultragenyx posted $673 million in 2025 revenue against a $575 million net loss, and announced workforce reductions. Commercial execution on any approval will carry weight.

For the week beginning August 17, macro events include the July FOMC minutes on Wednesday and a heavy earnings calendar — Walmart and Deere on Thursday, Target and Lowe's on Wednesday. The broader market closed the week ended August 14 with the S&P 500 up 0.4% for its third consecutive positive week, per STL News, while the University of Michigan's preliminary August sentiment index fell to 51, below forecasts of 55. For RARE shareholders, August 23 remains the date that matters. There is no known FDA precedent from the search results for a directly comparable approved gene therapy in rare metabolic disease, which makes the August 23 outcome both high-stakes and without a clear market template.